| REGISTERED NUMBER: |
| Unaudited Financial Statements |
| for the Year Ended 28 February 2026 |
| for |
| Alcyomics Limited |
| REGISTERED NUMBER: |
| Unaudited Financial Statements |
| for the Year Ended 28 February 2026 |
| for |
| Alcyomics Limited |
| Alcyomics Limited (Registered number: 06102853) |
| Contents of the Financial Statements |
| for the Year Ended 28 February 2026 |
| Page |
| Company Information | 1 |
| Balance Sheet | 2 |
| Notes to the Financial Statements | 4 |
| Alcyomics Limited |
| Company Information |
| for the Year Ended 28 February 2026 |
| DIRECTORS: |
| SECRETARY: |
| REGISTERED OFFICE: |
| REGISTERED NUMBER: |
| ACCOUNTANTS: |
| Chartered Accountants |
| Kepier House |
| Belmont Business Park |
| Durham |
| DH1 1TW |
| Alcyomics Limited (Registered number: 06102853) |
| Balance Sheet |
| 28 February 2026 |
| 2026 | 2025 |
| Notes | £ | £ |
| FIXED ASSETS |
| Intangible assets | 4 |
| Tangible assets | 5 |
| CURRENT ASSETS |
| Stocks |
| Debtors | 6 |
| Cash at bank |
| CREDITORS |
| Amounts falling due within one year | 7 | ( |
) | ( |
) |
| NET CURRENT ASSETS/(LIABILITIES) | ( |
) |
| TOTAL ASSETS LESS CURRENT LIABILITIES |
| CREDITORS |
| Amounts falling due after more than one year |
8 |
( |
) |
( |
) |
| NET LIABILITIES | ( |
) | ( |
) |
| CAPITAL AND RESERVES |
| Called up share capital | 11 |
| Share premium |
| Retained earnings | ( |
) | ( |
) |
| SHAREHOLDERS' FUNDS | ( |
) | ( |
) |
| The directors acknowledge their responsibilities for: |
| (a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
| (b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
| Alcyomics Limited (Registered number: 06102853) |
| Balance Sheet - continued |
| 28 February 2026 |
| The financial statements were approved by the Board of Directors and authorised for issue on |
| Alcyomics Limited (Registered number: 06102853) |
| Notes to the Financial Statements |
| for the Year Ended 28 February 2026 |
| 1. | STATUTORY INFORMATION |
| Alcyomics Limited is a |
| 2. | ACCOUNTING POLICIES |
| Basis of preparing the financial statements |
| There were no material departures from that standard. |
| The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year and also have been consistently applied within the same accounts. |
| Going concern |
| The directors assess whether the use of going concern is appropriate i.e. whether there are any material uncertainties related to events or conditions that may cast significant doubt on the ability of the company to continue as a going concern. The directors make this assessment in respect of a period of at least one year from the date the financial statements are approved. |
| The financial statements are prepared on the going concern basis which assumes that the company will continue to trade. If the company is unable to continue to trade, adjustments would be required to reduce the value of assets to their recoverable amounts, to provide for any further liabilities that might arise and to analyse long term liabilities as current liabilities. |
| Related party exemption |
| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions conducted at a market rate. |
| Turnover |
| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. |
| Income Recognition |
| The company recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and specific criteria have been met for each of the company's activities. |
| Intangible assets |
| Intangible assets are initially measured at cost. After initial recognition. intangible assets are measured at cost less any accumulated ammortisation and any accumulated impairment losses. |
| Development costs relate to intangible assets which are not yet complete and in use, therefore no amortisation has been charged. |
| Tangible fixed assets |
| Equipment | - |
| Tangible fixed assets are included at cost less accumulated depreciation and impairment. |
| Alcyomics Limited (Registered number: 06102853) |
| Notes to the Financial Statements - continued |
| for the Year Ended 28 February 2026 |
| 2. | ACCOUNTING POLICIES - continued |
| Government grants |
| Revenue based grants have been credited to the profit and loss account in the period to which they relate. |
| Capital based grants are accounted for using the accruals model and have been transferred to a deferred credit and released to the profit and loss account over the useful life of the asset, as disclosed above. |
| Stocks |
| Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. |
| Financial instruments |
| Basic financial instruments are recognised at amortised cost with changes recognised in profit and loss. |
| Taxation |
| Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit & Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
| Current or deferred taxation assets and liabilities are not discounted. |
| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
| Deferred tax |
| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
| Research and development |
| Expenditure on research and development is written off in the year in which it is incurred. |
| Foreign currencies |
| Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result. |
| Hire purchase and leasing commitments |
| Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter. |
| The interest element of these obligations is charged to profit or loss over the relevant period. The capital element of the future payments is treated as a liability. |
| Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease. |
| Pension costs and other post-retirement benefits |
| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate. |
| Alcyomics Limited (Registered number: 06102853) |
| Notes to the Financial Statements - continued |
| for the Year Ended 28 February 2026 |
| 2. | ACCOUNTING POLICIES - continued |
| Share based payments |
| Alcyomics Limited issues equity-settled share options to certain employees within the company. Equity-settled share-based payment transactions are measured at fair value (excluding the effect of non market-based vesting conditions) at the date of the grant. |
| The fair value determined at the grant date of the equity-settled share-based payments is expensed on a straight-line basis over the vesting year, based on Alcyomics Limited estimate of shares that will eventually vest, and adjusted for the effect of non market-based vesting conditions. |
| 3. | EMPLOYEES AND DIRECTORS |
| The average number of employees during the year was |
| 4. | INTANGIBLE FIXED ASSETS |
| Development |
| costs |
| £ |
| COST |
| At 1 March 2025 |
| and 28 February 2026 |
| NET BOOK VALUE |
| At 28 February 2026 |
| At 28 February 2025 |
| 5. | TANGIBLE FIXED ASSETS |
| Equipment |
| £ |
| COST |
| At 1 March 2025 |
| Additions |
| At 28 February 2026 |
| DEPRECIATION |
| At 1 March 2025 |
| Charge for year |
| At 28 February 2026 |
| NET BOOK VALUE |
| At 28 February 2026 |
| At 28 February 2025 |
| Alcyomics Limited (Registered number: 06102853) |
| Notes to the Financial Statements - continued |
| for the Year Ended 28 February 2026 |
| 5. | TANGIBLE FIXED ASSETS - continued |
| Fixed assets, included in the above, which are held under hire purchase contracts are as follows: |
| Equipment |
| £ |
| COST |
| Additions |
| At 28 February 2026 |
| DEPRECIATION |
| Charge for year |
| At 28 February 2026 |
| NET BOOK VALUE |
| At 28 February 2026 |
| 6. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 2026 | 2025 |
| £ | £ |
| Trade debtors |
| Other debtors |
| Prepayments and accrued income |
| 7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 2026 | 2025 |
| £ | £ |
| Bank loans and overdrafts |
| Hire purchase contracts (see note 9) |
| Trade creditors |
| Taxation and social security |
| Other creditors |
| Accruals and deferred income |
| 8. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |
| 2026 | 2025 |
| £ | £ |
| Bank loans - 1-2 years |
| Bank loans - 2-5 years |
| Hire purchase contracts (see note 9) |
| Directors' loan accounts | 426,152 | 459,787 |
| Alcyomics Limited (Registered number: 06102853) |
| Notes to the Financial Statements - continued |
| for the Year Ended 28 February 2026 |
| 9. | LEASING AGREEMENTS |
| Minimum lease payments under hire purchase fall due as follows: |
| 2026 | 2025 |
| £ | £ |
| Net obligations repayable: |
| Within one year |
| Between one and five years |
| 10. | SECURED DEBTS |
| The following secured debts are included within creditors: |
| 2026 | 2025 |
| £ | £ |
| Hire purchase contracts | 46,293 | - |
| Bank loans | 235,133 | 327,290 |
| Invoice factoring account | 99,828 | 57,165 |
| The bank loan and other loans are secured by fixed and floating charges over the assets of the company. |
| Hire puchase contracts are secured on the assets to which they relate. |
| 11. | CALLED UP SHARE CAPITAL |
| Allotted, issued and fully paid: |
| Number: | Class: | Nominal | 2026 | 2025 |
| value: | £ | £ |
| Ordinary | £0.10 | 100 | 100 |
| Ordinary A | £0.10 | 19 | 19 |
| Ordinary B | £0.10 | 6 | 6 |
| 125 | 125 |
| 12. | RELATED PARTY DISCLOSURES |
| There were no related party transactions other than those concluded under normal market condition, except for those shown below: |
| 2026 | 2025 |
| £ | £ |
| Amounts due to directors | 426,152 | 459,787 |
| No interest has been charged. |
| Alcyomics Limited (Registered number: 06102853) |
| Notes to the Financial Statements - continued |
| for the Year Ended 28 February 2026 |
| 13. | SHARE-BASED PAYMENT TRANSACTIONS |
| In September 2025, the company established an EMI scheme under which share options have been granted to certain key individuals. The scheme has a maximum vesting period of 15 years and is exercisable at the next eligible event. |
| In addition, employees must have remained in employment. Share options are to be settled through equity. There is no cash-based alternative. |
| The fair value recognised in the accounts for the year ended 28 February 2026 was a charge of £nil. |